HTG Molecular Announces Executive Transition Plan

HTG Molecular Diagnostics (Nasdaq:HTGM) a life science company whose mission is to advance precision medicine, announced a leadership transition plan in which TJ Johnson, Chief Executive Officer of HTG will assume the role of Executive Chairman of the Board of Directors of HTG.

As quoted in the press release:

“TJ has been a tremendous leader and a passionate advocate during his 11 years as CEO of the company.  His strategic vision and steadfast guidance have put HTG on a path of growth for years to come,” said Ann Hanham, Ph.D., Chair of HTG’s Board of Directors. “We are pleased to have another proven executive within HTG ready to lead the Company and continue to execute our strategy seamlessly through this transition.  John has been with HTG since 2011, participated in the public financing of the company and knows the business, the markets and customers very well.  He and TJ share a vision for the company, and we are thrilled to have TJ remain on the Board as our Executive Chair.”

TJ Johnson, CEO of HTG added, “It has been a tremendous honor to lead this incredibly talented team, and I couldn’t be more pleased to have John be named as my successor.  John is a well-respected executive, who has shown tremendous leadership qualities and has been a trusted “co-pilot” with me over the many years I have known him. HTG is on solid footing, the management team is firmly in place, and I think now is an ideal time for me to step into the Executive Chair role where I can and will continue to focus on strategic growth and business development opportunities for HTG while supporting John and the team. I have full confidence in a seamless transition.”

Click here to read the full press release.